GLAVINE PAUL (Chief Growth Officer) purchased 2.4% of their position (100K shares) of HELUS PHARMA INC. on the open market
Open‑market purchase worth $1.25M — a small addition. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 9/11/2026ACC: 0000912282-26-001264
Officer· Chief Growth Officer
Since Aug 2026
+100K
Net shares
Net buyer
$1.25M
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
100K acquired
Non-Derivative Transactions1
Common Shares
Direct
Shares
+100K
Price / share
$12.47
Trade value
$1.25M
% of position
2.4%
9/8/2026
4.17M→4.27M
Total
Net shares
+100K
Net value
$1.25M
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 9/8/2026 | P · Purchase | +100K | $12.47 | $1.25M | 2.4% | 4.17M | 4.27M |
| Total | +100K | $1.25M | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Shares
IndirectShares owned230.94K
Total
230.94K indirect230.94K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Shares | 230.94K | Indirect |
| Total | 230.94K | 230.94K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported